{
}
Kenvue Inc. reported a quarterly EPS of $0.26, meeting expectations, with a return on equity of 20.97% and a net margin of 6.66%. The company announced a quarterly dividend of $0.205, yielding 3.45%, while analysts maintain a "Hold" rating with an average target price of $24.00. Institutional investors own 97.64% of Kenvue's stock, reflecting strong market interest.
Kenvue Inc, a consumer health company, has 97.64% of its stock owned by institutional investors and hedge funds. Analysts have mixed ratings on the stock, with a consensus "Hold" and a price target of $24.00, while Barclays recently raised its target to $23.00. The company reported an EPS of $0.26, meeting expectations, and has a market cap of $44.95 billion.
Barclays identifies a buying opportunity in MedTech stocks following recent declines in key players like Baxter, Abbott, and Medtronic, despite their strong year-to-date performance. The sector has outperformed the S&P 500, with notable gains in Diabetes and other groups, while individual stocks like Obio and Alphatec have surged. Barclays remains optimistic about the sector's potential for upside amid recent volatility.
UBS has lowered its price target for Kenvue Inc. to $21 from $23 while maintaining a neutral rating. Kenvue is a leader in consumer healthcare, offering a diverse range of products across self-care (41.8%), personal care (29.9%), and beauty and skin care (28.3%), with significant sales in North America (49.3%).
Huawei has secured the sixth position in the 2024 Global Top 100 R&D Investment Companies ranking, investing over 19 billion euros in research and development last year. This achievement makes Huawei the highest-ranked Chinese firm, surpassing competitors like Samsung, Intel, and Qualcomm. The top five companies include Alphabet, Meta, Apple, Microsoft, and Volkswagen, with Alphabet leading at 39.8 billion euros in R&D investment.
Johnson & Johnson's stock saw significant insider activity, with Director Mark A. Weinberger acquiring 1,000 shares, marking an infinite increase in ownership. Institutional investors hold 69.55% of the stock, while analysts maintain a "Moderate Buy" rating, with a consensus target price of $170.44. The company recently reported a quarterly EPS of $2.04, exceeding expectations, and announced a dividend of $1.24 per share, reflecting a yield of 3.28%.
In Asian forex trading, the yen remained stable against the dollar ahead of the Bank of Japan's interest rate decision, while the dollar slightly rose against the yuan and Swiss franc. Oil prices dipped amid speculation of increased OPEC production, with North Sea Brent crude at $78.73 per barrel. US markets saw gains, with the Dow Jones up 0.3% and Netflix experiencing significant subscriber growth, boosting its shares nearly 10%. Concerns over Trump's tariff plans on Chinese imports weighed on the dollar, which faced headwinds as clarity on trade negotiations remained elusive.
Key US equity indices saw significant weekly gains, with the S&P 500 up 3.2% and the Dow reaching 43,487, bolstered by strong earnings and lighter-than-expected pricing data. Despite a cautious consolidation in technical analysis, the market remains above long-term moving averages, indicating a positive bias. Upcoming executive actions and earnings reports from major companies like Johnson & Johnson and Procter & Gamble are anticipated to influence market dynamics further.
At the J.P. Morgan Healthcare Conference, Pfizer CEO Albert Bourla addressed an impending $17B 'LOE wave' due to patent losses, while highlighting acquisitions expected to generate $20B in annual sales by 2030. Johnson & Johnson announced a $14.6B acquisition of Intra-Cellular Therapies, aiming to enhance its portfolio with the FDA-approved drug Caplyta. Meanwhile, Moderna revealed a significant cut to its 2025 sales guidance, prompting a 20% drop in its stock.
Intra-Cellular Therapies (ITCI) shares surged nearly 15% following a settlement with Sandoz over Caplyta patent litigation, allowing Sandoz to sell generics starting July 1, 2040, under certain conditions. This agreement secures ITCI's market position for Caplyta, its sole revenue-generating product, which saw a 46% sales increase in early 2024. The company continues to pursue similar litigation against other parties.
Johnson & Johnson
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Kenvue Inc reports steady earnings and announces quarterly dividend payout
10:28 31.03.2025
kenvue stock analysis institutional ownership and analyst ratings update
Royal Bank of Canada
Barclays PLC
Piper Sandler Cos
UBS Group AG
Johnson & Johnson
Citigroup Inc.
USA
Show more
14:47 28.03.2025
Barclays identifies buying opportunities in MedTech stocks amid recent pullbacks
15:44 24.03.2025
ubs lowers kenvue price target to twenty one maintains neutral rating
17:21 07.02.2025
Huawei ranks sixth in 2024 global R&D investment companies list
Euro
Johnson & Johnson
Apple Inc.
Microsoft Corporation
VOLKSWAGEN
Hoffmann-La Roche AG
Google Inc.
USA
CHN
JPN
Show more
07:34 03.02.2025
insider activity and institutional investments boost confidence in johnson and johnson
10:32 29.01.2025
stock market update smi slightly lower as autoneum shares slump
Swiss Franc
Euro
United States Dollar
Japanese Yen
Chinese Yuan
Logitech International S.A.
Huber+Suhner AG
Lemonade, Inc.
Johnson & Johnson
DocMorris AG
Procter & Gamble Co
Axon Partners Group, S.A.
RICHEMONT, Intellectual Property Services
Barry Callebaut AG
OC Oerlikon Corp AG, Pfaffikon
Galenica AG
AVOLTA N
Oracle AI USD
USA
MEX
JPN
CHN
CAN
Joe Biden
Donald Trump
Kyle Rodda
Show more
06:05 23.01.2025
strong week for us equities amid lighter pricing data and earnings boost
09:08 20.01.2025
jpmorgan conference highlights major acquisitions and strategic plans in healthcare industry
United States Dollar
Intra-Cellular Therapies, Inc.
Johnson & Johnson
Vertex, Inc.
Pfizer Inc.
Moderna, Inc.
USA
Albert Bourla
Joaquin Duato
Reshma Kewalramani
Show more
20:35 13.01.2025
intra-cellular therapies stock surges after caplyta patent litigation settlement
United States Dollar
Novartis AG
Sandoz Group AG
Intra-Cellular Therapies, Inc.
Johnson & Johnson
USA
Show more
17:40 13.01.2025
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
Central Bank Actions
GDP Growth & Recession Forecasts
CEO Changes
Global Trade Developments
Industry Mergers & Acquisitions
Financial Scams and Security
Market Analysis and Predictions
Inflation and Monetary Impact
Government Policies
Government Economic Policies
Supply Chain Management
Domestic Politics
Workplace Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Bank of America Corporation
Barclays PLC
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Credit Suisse Strategic Income I
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
Swiss Re AG
Beazley plc
UBS AG
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Canadian Dollar
Australian Dollar
United Arab Emirates Dirham
Saudi Riyal
South Korean Won
Danish Krone
Offshore Chinese Yuan
Hong Kong Dollar
Mexican Peso
Indonesian Rupiah
Malaysian Ringgit
Vietnamese Đồng
People: